LYAR Antibodies

Structure of LYAR

LYAR is a zinc finger protein with a molecular weight of approximately 55-60 kDa. Its precise molecular weight may vary among different transcripts and post-translational modifications.

This protein is composed of approximately 500 amino acids, and its core function relies on typical C2H2-type zinc finger domains, which mediate interactions with nucleic acids and proteins. The tertiary structure of LYAR forms a compact spherical conformation, with its zinc finger modules arranged like "fingers", which can precisely recognize and bind to specific DNA or RNA sequences, thus playing a key role in ribosome biosynthesis and cell cycle regulation.

Fig. 1 LYAR-Mediated Recruitment of BRD2-KAT7 Drives H4 Acetylation and rDNA Transcription.¹

Key structural properties of LYAR:

• Typical C2H2 zinc finger domain is the core module
• Nucleolus localization signals ensure their functional localization within the cell nucleus
• Zinc ion coordination system maintains structural stability and nucleic acid binding ability

Functions of LYAR

The main function of the LYAR gene is to regulate cell proliferation and survival. However, it is also involved in a variety of cell biological processes, including ribosomal biogenesis and cell fate determination.

LYAR plays a key role in integrating cell growth signals and proliferation execution by coordinating transcriptional regulation and nucleolar function. Its functional network is complex and at the core.

Applications of LYAR and LYAR Antibody in Literature

1. Wu, Yupeng, et al. "LYAR promotes colorectal cancer progression by upregulating FSCN1 expression and fatty acid metabolism." Oxidative Medicine and Cellular Longevity 2021.1 (2021): 9979707. https://doi.org/10.1155/2021/9979707

Research has found that LYAR is highly expressed in colorectal cancer and promotes metastasis. The mechanism is to up-regulate FSCN1, thereby affecting fatty acid metabolism and ultimately enhancing the migration and invasion abilities of cancer cells.

2. Izumikawa, Keiichi, et al. "LYAR potentiates rRNA synthesis by recruiting BRD2/4 and the MYST-type acetyltransferase KAT7 to rDNA." Nucleic Acids Research 47.19 (2019): 10357-10372. https://doi.org/10.1093/nar/gkz747

This study found that LYAR activates rRNA transcription and promotes tumorigenesis by separately recruiting the BRD2-KAT7 and BRD4-KAT7 complexes to the rDNA region, synergically increasing the acetylation level of histone H3/H4.

3. Wu, Yupeng, et al. "LYAR promotes colorectal cancer cell mobility by activating galectin-1 expression." Oncotarget 6.32 (2015): 32890. https://doi.org/10.18632/oncotarget.5335

Studies have shown that highly expressed LYAR enhances the mobility and invasion ability of colorectal cancer cells by directly transcriptional activating LGALS1 (galectin-1), revealing a new carcinogenic mechanism.

4. Yang, Cha, et al. "The nucleolar protein LYAR facilitates ribonucleoprotein assembly of influenza A virus." Journal of Virology 92.23 (2018): 10-1128. https://doi.org/10.1128/JVI.01042-18

This study found that the host protein LYAR interacts with the vRNP complex of influenza A virus, enhancing viral RNA synthesis by promoting the assembly of vRNP, thereby facilitating important viral replication.

5. Zuccato, Cristina, et al. "The rs368698783 (G> A) Polymorphism Affecting LYAR Binding to the Aγ-Globin Gene Is Associated with High Fetal Hemoglobin (HbF) in β-Thalassemia Erythroid Precursor Cells Treated with HbF Inducers." International Journal of Molecular Sciences 24.1 (2023): 776. https://doi.org/10.3390/ijms24010776

This study found that the rs368698783 polymorphism of the LYAR gene reduced its binding efficiency with the promoter of the Aγ -globin gene, thereby upregulating the basal and induced levels of fetal hemoglobin (HbF), providing a basis for the precise treatment of β -thalassemia.

Creative Biolabs: LYAR Antibodies for Research

Creative Biolabs specializes in the production of high-quality LYAR antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom LYAR Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our LYAR antibodies, custom preparations, or technical support, contact us at email.